COMMUNIQUÉS West-GlobeNewswire
-
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
09/03/2026 -
FocusMax Cognitive Support Claims Evaluated: Latest 2026 Consumer Research Report on FocusMax Ingredients, Proprietary Blend Dosing, and Cognitive Supplement Research
09/03/2026 -
Kristen Boehmer of Empowered Lyfe Partners with MD Logic Health to Launch Daily Colostrum, an Advanced Low Molecular Weight Bioactive Colostrum
09/03/2026 -
VisiFlora Gut-Eye Vision Support Claims Examined: 2026 Consumer Report on the 22-Ingredient Formula, Gut-Eye Axis Research, and What Adults Researching Vision Supplements Should Verify
09/03/2026 -
The Great Give Back brings community together in support of Royal Columbian Hospital
09/03/2026 -
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026 -
Choice Healthcare Services Announces Expansion of Children’s Choice Pediatric Dentistry Locations in California
09/03/2026 -
MemoTril Consumer Concerns Under Investigation: Critiquing The Memo Tril Claims
09/03/2026 -
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
09/03/2026 -
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
09/03/2026 -
Hydration Room Opens in San Francisco’s Cow Hollow, Introducing Nurse-Administered, Medically Supervised IV Therapy Designed for Sustained Performance and Recovery
09/03/2026 -
Surgery Partners, Inc. to Present at Upcoming Investor Conference
09/03/2026 -
Radiant Health Centers Announces Honorees for 40th Annual Gala Celebrating Four Decades of Compassionate Care
09/03/2026 -
GENFIT reçoit la désignation Orphan Drug de la FDA pour NTZ dans le traitement de l’ACLF
09/03/2026 -
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026 -
Zealand Pharma to participate in upcoming investor conferences in March 2026
09/03/2026 -
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
09/03/2026 -
EssilorLuxottica: Déclaration de transactions sur actions propres
09/03/2026 -
Transactions in Connection with Share Buy-back Program
09/03/2026
Pages